Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population-based multicentre cohort study

Journal of Internal Medicine

Volumn 278, Issue 2, 2015, Pages 185-192

  Bartoloni, E ^a   Baldini, C ^b   Schillaci, G ^c   Quartuccio, L ^d   Priori, R ^e   Carubbi, F ^f   Bini, V ^a   Alunno, A ^a   Bombardieri, S ^b   De Vita, S ^d   Valesini, G ^e   Giacomelli, R ^f   Gerli, Roberto ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c University Hospital of Terni   (Italy)

^d UNIVERSITY OF UDINE   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

atherosclerosis; autoimmune disease; cardiovascular disease risk factors; Sj gren's syndrome

Indexed keywords

ANTINUCLEAR ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CRYOGLOBULIN; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LA ANTIBODY; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RHEUMATOID FACTOR; RO ANTIBODY; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOPENIA; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGAMMAGLOBULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOCOMPLEMENTEMIA; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LOW DRUG DOSE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OBESITY; PAROTID ENLARGEMENT; PRIORITY JOURNAL; PURPURA; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEROLOGY; SEX DIFFERENCE; SIALOADENITIS; SJOEGREN SYNDROME; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; XEROPHTHALMIA; XEROSTOMIA; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; ITALY; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; PROCEDURES; SJOGREN'S SYNDROME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SJOGREN'S SYNDROME; YOUNG ADULT;

EID: 84928726957     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12346     Document Type: Article

References (36)

1. Canto JG, Kiefe CI, Rogers WJ et al. NRMI Investigators Atherosclerotic risk factors and their association with hospital mortality among patients with first myocardial infarction (from the National Registry of Myocardial Infarction). Am J Cardiol 2012; 164: 801–6.
2. Kuo F, Gardener H, Dong C et al. Traditional cardiovascular risk factors explain the minority of the variability in carotid plaque. Stroke 2012; 43: 1755–60.
3. Herder M, Harald Johnsen S, Arntzen K, Mathiesen E. Risk factors for progression of carotid intima-media thickness and total plaque area. A 13-year follow-up study: the Tromsø Study. Stroke 2012; 43: 1818–23.
4. Kao A, Lertratanakul A, Elliott J et al. Relation of carotid intima-media thickness and plaque with incident cardiovascular events in women with systemic lupus erythematosus. Am J Cardiol 2013; 112: 1025–32.
5. Boyer J, Gourraud P, Cantagrel A, Davignon J, Constantin A. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 2011; 78: 179–83.
6. Sen D, Gonzàlez-Mayda M, Brasington RD. Cardiovascular disease in rheumatoid arthritis. Rheum Dis Clin North Am 2014; 40: 27–49.
7. Gonzalez A, Maradit Kremers H, Crowson CS et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008; 67: 64–9.
8. Myasoedova E, Crowson C, Maradit-Kremers H et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011; 70: 482–7.
9. Bartoloni E, Shoenfeld Y, Gerli R. Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res (Hoboken) 2011; 2: 178–83.
10. Gustafsson JT, Svenungsson E. Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. Autoimmunity 2014; 47: 67–76.
11. Peri Y, Agmon-Levin N, Theodor E, Shoenfeld Y. Sjögren's syndrome, the old and the new. Best Pract Res Clin Rheumatol 2012; 26: 105–17.
12. Gerli R, Vaudo G, Bartoloni Bocci E et al. Functional impairment of the arterial wall in primary Sjögren's syndrome: combined action of immunologic and inflammatory factors. Arthritis Care Res (Hoboken) 2010; 62: 712–8.
13. Vaudo G, Bartoloni Bocci E, Shoenfeld Y et al. Precocious intima-media thickening in patients with primary Sjögren's syndrome. Arthritis Rheum 2005; 52: 3890–7.
14. Pirildar T, Tikiz C, Özkaya S et al. Endothelial dysfunction in patients with primary Sjögren's syndrome. Rheumatol Int 2005; 25: 536–9.
15. Rachapalli S, Kiely P, Bourke B. Prevalence of abnormal ankle brachial index in patients with primary Sjögren's syndrome. Clin Rheumatol 2009; 28: 587–90.
16. Atzeni F, Sarzi-Puttini P, Signorello MC et al. New parameters for identifying subclinical atherosclerosis in patients with primary Sjögren's syndrome: a pilot study. Clin Exp Rheumatol 2014; 32: 361–8.
17. Pèrez-De-Lis M, Akasbi M, Sisò A et al. Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients. Lupus 2010; 19: 941–8.
18. Gerli R, Bartoloni Bocci E, Vaudo G, Marchesi S, Vitali C, Shoenfeld Y. Traditional cardiovascular risk factors in primary Sjögren's syndrome: role of dyslipidaemia. Rheumatology 2006; 45: 1580–1.
19. Vitali C, Bombardieri S, Moutsopoulos HM et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993; 36: 340–7.
20. Vitali C, Bombardieri S, Jonsson R et al. for the European Study Group on Classification Criteria for Sjögren's syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554–8.
21. Baldini C, Pepe P, Quartuccio L et al. Primary Sjögren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology 2013; 53: 839–44.
22. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–47.
23. Shoenfeld Y, Gerli R, Doria A et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337–47.
24. Karabulut G, Kitapcioglu G, Inal V et al. Cigarette smoking in primary Sjögren's syndrome: positive association only with ANA positivity. Mod Rheumatol 2011; 21: 602–7.
25. Juarez M, Toms TE, de Pablo P et al. Cardiovascular risk factors in women with primary Sjögren's syndrome: United Kingdom primary Sjögren's syndrome Registry results. Arthritis Care Res (Hoboken) 2014; 66: 757–64.
26. Gerli R, Sherer Y, Vaudo G et al. Early atherosclerosis in rheumatoid arthritis: effects of smoking on thickness of the carotid artery intima media. Ann N Y Acad Sci 2005; 1051: 281–90.
27. Manthorpe R, Benoni C, Jacobsson L et al. Lower frequency of focal lip sialadenitis (focus score) in smoking patients. Can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjögren's syndrome? Ann Rheum Dis 2000; 59: 54–60.
28. Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD. Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol 2010; 6: 445–51.
29. Ramos-Casals M, Brito-Zeròn P, Sisò A et al. High prevalence of serum metabolic alterations in primary Sjögren's syndrome: influence on clinical and immunological expression. J Rheumatol 2007; 34: 754–61.
30. Lodde B, Sankar V, Kok M, Leakan R, Tak P, Pillemer S. Serum lipid levels in Sjögren's syndrome. Rheumatology 2006; 45: 481–4.
31. Cruz W, Fialho S, Morato E et al. Is there a link between inflammation and abnormal lipoprotein profile in Sjögren's syndrome? Joint Bone Spine 2010; 77: 229–31.
32. Gofinet Pasoto S, Chakkour H, Natalino R et al. Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren's syndrome. Clin Rheumatol 2012; 31: 1331–8.
33. Zöller B, Li X, Sundquist J, Sundquist K. Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. BMC Neurol 2012; 12: 41.
34. Zöller B, Li X, Sundquist J, Sundquist K. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. PLoS ONE 2012; 3: e33442.
35. Chiang C, Liu C, Chen P et al. Primary Sjögren's syndrome and the risk of acute myocardial infarction: a nationwide study. Acta Cardiol Sin 2013; 29: 124–31.
36. Dichgans M, Malik R, König IR et al. Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. Stroke 2014; 45: 24–36.